Forma Medical
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$218Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
97clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Optimalmtp $143K associated (2023-2025)
- Optimalakin $43K associated (2023-2025)
- Optimalht $7,231 associated (2023-2025)
- Optimal Mtp $6,803 associated (2023-2025)
- Optimal Iadipus $5,200 associated (2023-2025)
- Otimalmtp $4,144 associated (2023-2025)
- Optimal Iapidus $2,865 associated (2023-2025)
- Optimal Iht $2,311 associated (2023-2025)
- Optimamtp $1,640 associated (2023-2025)
- Optimaht $1,560 associated (2023-2025)
- Optimal Tmt $205 associated (2023-2025)
- Optimal $147 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Jesse Doty | Chattanooga, TN | Orthopaedic Surgery | $91,366.65 |
| Austin Davidson | Knoxville, TN | Orthopaedic Surgery | $36,247.06 |
| Christopher Hyer | Worthington, OH | Foot & Ankle Surgery | $11,929.05 |
| Benjamin Potter | Kingsport, TN | Foot & Ankle Surgery | $8,987.08 |
| Scott Hanauer | Englewood, NJ | Foot & Ankle Surgery | $7,880.12 |
| Jeremy Walters | Suffolk, VA | Podiatrist | $6,284.89 |
| Jeffery Zimmerman | Shillington, PA | Podiatrist | $5,666.51 |
| John Thompson | Sandy Springs, GA | Foot & Ankle Surgery | $5,110.27 |
| Erroll Bailey | Atlanta, GA | Orthopaedic Surgery | $4,450.72 |
| Thanh Dinh | Boston, MA | Podiatrist | $3,357.67 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.